NCT02959463View on ClinicalTrials.gov

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Pleural Malignant Mesothelioma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

RADIATION

Palliative Radiation Therapy

Undergo palliative radiation therapy

BIOLOGICAL

Pembrolizumab

Given IV

RADIATION

Radiation Therapy

Undergo hemithoracic radiation therapy

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER